Kenneth A. Getz


Anticipating Digital Transformation of the Drug Development Workforce

The drug development sector is embracing technologies and digital methods that were previously not as widely used due to the COVID-19 global health crisis.

Tracking Trial Cost Drivers: The Impact of Comparator Drugs and Co-Therapies

New research from the Tufts Center for the Study of Drug Development identifies a significant contributor to the rising cost of clinical trials-the first step in meeting a growing strategic imperative to help senior management and the regulatory community craft new approaches to make trials more efficient in delivering results to clinicians and patients.